Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents
Journal of Medicinal Chemistry · 09.11.2023 · 66 (21) · 14669-14682
DOI: 10.1021/acs.jmedchem.3c01183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.10.2023. Verfasst von Weiyuan Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China. Hauptthemen laut MEDLINE: Organometallic Compounds, Liver Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Wenzhou Municipal Science and Technology Bureau, University of Chinese Academy of Sciences, Anhui Laboratory of Molecule-Based Materials, Anhui Normal University.
Abstract (Originalsprache)
The leakage of gadolinium ions (Gd3+) from commercial Gd3+-based contrast agents (GBCAs) in patients is currently the major safety concern in clinical magnetic resonance imaging (MRI) scans, and the lack of task-specific GBCAs limits its usage in the early detection of disease and imaging of specific biological regions. Herein, ultrastable GBCAs were constructed via decorating chiral Gd-DOTA with a phenylic analogue to one of the pendent arms, and the stability constant was determined as high as 27.08, accompanied by negligible decomplexation in 1 M of HCl over 2 years. A hepatic-specific chiral Gd-DOTA was screened out as a potential alternative to commercial Gd-EOB-DTPA, while combination with functional molecules favored chiral Gd-DOTA as tumor targeting probes. Therefore, the novel chiral Gd-DOTA is believed to be an ideal platform for designing the next generation of GBCAs for various clinical purposes due to its outstanding inert nature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang 325000, China.
- Department of Radiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
- Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, Guangdong 518057, China.
- Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
ORCID-Profile: Min Wu, Jianliang Shen, Fangfu Ye, Lixiong Dai
Förderung
- Wenzhou Municipal Science and Technology Bureau
- University of Chinese Academy of Sciences
- Anhui Laboratory of Molecule-Based Materials, Anhui Normal University
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Xu, W., Ye, X., Wu, M., Jiang, X., Hugo Tse, L. H., Gu, Y., Shu, K., Xu, L., Jian, Y., Mo, G., Xu, J., Ding, Y., Gao, R., Shen, J., Ye, F., Yan, Z., & Dai, L. (2023). Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents. Journal of Medicinal Chemistry, 66(21), 14669-14682. https://doi.org/10.1021/acs.jmedchem.3c01183
Vancouver
Xu W, Ye X, Wu M, Jiang X, Hugo Tse LH, Gu Y, et al. Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents. Journal of Medicinal Chemistry. 2023;66(21):14669-14682. doi:10.1021/acs.jmedchem.3c01183
BibTeX
@article{Xu2023,
author = {Xu, Weiyuan and Ye, Xinjian and Wu, Min and Jiang, Xin and Hugo Tse, Lik Hang and Gu, Yanjuan and Shu, Kun and Xu, Liuhui and Jian, Yong and Mo, Gengshen and Xu, Jiao and Ding, Yinghui and Gao, Ruonan and Shen, Jianliang and Ye, Fangfu and Yan, Zhihan and Dai, Lixiong},
title = {Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {21},
pages = {14669--14682},
doi = {10.1021/acs.jmedchem.3c01183}
}
EUVIMED